Diasome Pharmaceuticals is dedicated to improving the lives of Type 1 and Type 2 Diabetes patients. Its patented nanotechnology targeted delivery systems have demonstrated preferential delivery of insulin to the liver. Diasome Pharmaceuticals is headquartered outside of Philadelphia, Pennsylvania with R&D facilities in Cleveland, Ohio.